This week’s issue covers developments shaping access to HIV prevention and the future of US biomedical research, including new pathways to accelerate access to lenacapavir for HIV PrEP, calls for ...

An analysis by Jirair Ratevosian of the Duke Global Health Institute looked comprehensively at AI-related abstracts, key themes from use cases, and emerging trends at AIDS 2026. His review shows the ...

Regulatory approvals, pending decisions, and appeals as of September 2026. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on ...

We believe that the struggle to end the AIDS epidemic depends on delivering effective HIV prevention, which in turn depends on resilient health systems incorporating policies and practices that ...

The US National Institutes of Health (NIH) signs a 10-year agreement that could move significant NIAID research funding to the Department of Defense, as NIAID separately proposes a major restructuring ...

New York City, September 12, 2024 – AVAC welcomes the groundbreaking results of the PURPOSE 2 HIV prevention study of twice-yearly injectable lenacapavir for PrEP among 3,200 cisgender men, ...

Our team compiled a list of AVAC’s top 10 takeaways from AIDS 2026. These topics sparked discussions and ideas among our team and AVAC’s larger partner network, and will carry our work well into the ...

In support of Dr. Anthony Fauci, AVAC submitted a letter to the Committee on Homeland Security and Governmental Affairs ahead of a Congressional hearing focused on the origins of COVID-19. This letter ...

HIV cure research is making meaningful strides toward strategies that could transform the future of HIV care, as news that immune-based therapies and broadly neutralizing antibodies may one day make ...

The call to collective responsibility followed presentation of CROI’s inaugural Lifetime Achievement Award to former Director of the National Institute of Allergy and Infectious Diseases (NIAID) Carl ...

New York City, June 20, 2024 – AVAC welcomes the groundbreaking results of the PURPOSE 1 HIV prevention study among adolescent girls and young women in South Africa and Uganda. Preliminary safety and ...

AVAC and Access Bridge applaud Merck’s announcement today that it has granted seven direct licenses to generic manufacturers to produce their investigational monthly pill for HIV prevention, known as ...